Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort
- PMID: 20025692
- PMCID: PMC2852497
- DOI: 10.1111/j.1365-2982.2009.01442.x
Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort
Abstract
BACKGROUND Abnormalities of colonic motility were reported in relatively small studies of patients with lower functional gastrointestinal disorders (FGID) including irritable bowel syndrome (IBS). The influence of gender and body mass on the observed motor pathophysiology is unclear. We sought to compare colonic transit in patients within different lower FGID subgroups and healthy controls, controlling for gender and BMI, and to determine whether BMI independently influences colonic motility. METHODS We evaluated a scintigraphic gastrointestinal and colonic transit database of 287 lower FGID patients associated with constipation (IBS-C, or functional constipation, n = 118), diarrhoea (IBS-D or functional diarrhoea, n = 139) or mixed bowel function (IBS-M, n = 30) and 170 healthy controls. We measured colon filling at 6 h (CF 6 h), and overall colonic transit at 8, 24 and 48 h. KEY RESULTS Colon filling at 6 h did not differentiate health from FGID. Colonic transit was abnormal at 24 h (GC24 of <1.50 or >3.86) in 29.7% of all lower FGID patients. There was a significant overall association between colonic transit and subject group (healthy controls and FGID subgroups) at 8 (P = 0.01), 24 (P < 0.001) and 48 h (P < 0.001) in particular for those with diarrhoea or constipation at 24 and 48 h (P < 0.05), even after adjusting for age, gender and BMI. In addition, BMI was associated with colonic transit after adjusting for age, gender and subject group. CONCLUSIONS & INFERENCES Abnormal transit is documented non-invasively with scintigraphy in 30% of lower FGID patients; transit measurement may help document pathophysiology and inform selection of therapy in lower FGID.
Figures




Similar articles
-
Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions.Neurogastroenterol Motil. 2010 Apr;22(4):415-23, e95. doi: 10.1111/j.1365-2982.2009.01441.x. Epub 2009 Dec 18. Neurogastroenterol Motil. 2010. PMID: 20025675 Free PMC article.
-
Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.Neurogastroenterol Motil. 2011 Nov;23(11):995-9, e458. doi: 10.1111/j.1365-2982.2011.01772.x. Epub 2011 Aug 24. Neurogastroenterol Motil. 2011. PMID: 21883702 Free PMC article.
-
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.Clin Gastroenterol Hepatol. 2004 Oct;2(10):895-904. doi: 10.1016/s1542-3565(04)00391-x. Clin Gastroenterol Hepatol. 2004. PMID: 15476153 Clinical Trial.
-
Colonic motility in health and disease.Gastroenterol Clin North Am. 1996 Mar;25(1):147-62. doi: 10.1016/s0889-8553(05)70369-1. Gastroenterol Clin North Am. 1996. PMID: 8682570 Review.
-
Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.Can J Gastroenterol. 1999 Mar;13 Suppl A:50A-65A. doi: 10.1155/1999/183697. Can J Gastroenterol. 1999. PMID: 10202210 Review.
Cited by
-
Washed microbiota transplantation improves symptoms and intestinal barrier function in patients with functional bowel disorders: a propensity-score matching analysis.BMC Gastroenterol. 2024 Jan 23;24(1):45. doi: 10.1186/s12876-024-03131-z. BMC Gastroenterol. 2024. PMID: 38262980 Free PMC article.
-
Sex as a biological variable in irritable bowel syndrome.Neurogastroenterol Motil. 2020 Jul;32(7):e13802. doi: 10.1111/nmo.13802. Epub 2020 Jan 13. Neurogastroenterol Motil. 2020. PMID: 31943595 Free PMC article. Review.
-
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut-brain interaction.Gut. 2023 Nov 24;72(12):2372-2380. doi: 10.1136/gutjnl-2023-330542. Gut. 2023. PMID: 37666657 Free PMC article. Review.
-
Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders.J Neurogastroenterol Motil. 2018 Jul 30;24(3):367-386. doi: 10.5056/jnm18071. J Neurogastroenterol Motil. 2018. PMID: 29969855 Free PMC article. Review.
-
The bile acid TGR5 membrane receptor: from basic research to clinical application.Dig Liver Dis. 2014 Apr;46(4):302-12. doi: 10.1016/j.dld.2013.10.021. Epub 2014 Jan 9. Dig Liver Dis. 2014. PMID: 24411485 Free PMC article. Review.
References
-
- Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–8. - PubMed
-
- Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2671–6. - PubMed
-
- Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1468–76. - PubMed
-
- Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003;284:G558–66. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical